Daniel M. Muldoon

Memorial Sloan Kettering Cancer Center

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Chaitanya Bandlamudi

Molecular Oncology (United States)

307

Marc Ladanyi

Memorial Sloan Kettering Cancer Center

305

Federica Pecci

University of Parma

302

Adam J. Schoenfeld

Memorial Sloan Kettering Cancer Center

302

Joao V. Alessi

Dana-Farber Cancer Institute

302

Giuseppe Lamberti

University of Bologna

302

Biagio Ricciuti

Dana-Farber Cancer Institute

302

Mark M. Awad

Dana-Farber Cancer Institute

302

Alessandro Di Federico

Dana-Farber Cancer Institute

301

Arielle Elkrief

Centre Hospitalier de l’Université de Montréal

301

Cooperative Institutions

Memorial Sloan Kettering Cancer Center

Kettering University

Cornell University

Harvard University

Dana-Farber Cancer Institute

University of Minnesota

Brigham and Women's Hospital

Molecular Oncology (United States)

Weill Cornell Medicine

Dana-Farber Brigham Cancer Center

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Supplementary Figure S9 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer

Rohit Thummalapalli Biagio Ricciuti Chaitanya Bandlamudi Daniel M. Muldoon Hira Rizvi

Frequency of long-term response (LTR) and short-term response (STR) according to composite PD-L1 and tumor mutational burden (TMB) status.

Immune checkpoint

10.1158/1078-0432.24473368

Cite

Citations (0)

Supplementary Figure 15 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of ATM Mutations in Non–Small Cell Lung Cancer

Biagio Ricciuti Arielle Elkrief Joao V. Alessi Xinan Wang Yvonne Li

Supplementary Figure 15. (A) Objective response rate, (B) progression-free survival, and (C) overall survival to chemo-immunotherapy among patients with advanced/metastatic PD-L1 negative (<1%) NSCLC, according to ATM mutation status. (D) Objective response rate, (E) progression-free survival, and (F) overall survival to PD-(L)1 immune checkpoint blockade in combination with platinum doublet chemotherapy among patients with advanced/metastatic PD-L1 intermediate (1-49%) NSCLC, according to ATM mutation status. (G) Objective response rate, (H) progression-free survival, and (I) overall survival to PD-(L)1 immune checkpoint blockade in combination with platinum doublet chemotherapy among patients with advanced/metastatic PD-L1 high (≥50%) NSCLC, according to ATM mutation status.

Immune checkpoint

Progression-free survival

10.1158/1078-0432.23627008.v1

Cite

Citations (0)

Supplementary Figure 4. from Clinicopathologic, Genomic, and Immunophenotypic Landscape of ATM Mutations in Non–Small Cell Lung Cancer

Biagio Ricciuti Arielle Elkrief Joao V. Alessi Xinan Wang Yvonne Li

Supplementary Figure 4. (A) Volcano plot showing gene mutations significantly enriched among NSCLCs harboring ATM missense mutations that were predicted to benign in silico versus NSCLCs without any ATM mutation. (B) Volcano plot showing gene mutations significantly enriched among ATMWT and ATMMUT samples in the TCGA-NSCLC cohort.

10.1158/1078-0432.23626945

Cite

Citations (0)

Supplementary Table 7 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of ATM Mutations in Non–Small Cell Lung Cancer

Biagio Ricciuti Arielle Elkrief Joao V. Alessi Xinan Wang Yvonne Li

Supplementary Table 7. Baseline clinicopathologic features of patients with ATM mutated and ATM wild-type NSCLCs which underwent multiplexed immunofluorescence at the DFCI.

Table (database)

10.1158/1078-0432.23626909.v1

Cite

Citations (0)

Supplementary Figure 22. from Clinicopathologic, Genomic, and Immunophenotypic Landscape of ATM Mutations in Non–Small Cell Lung Cancer

Biagio Ricciuti Arielle Elkrief Joao V. Alessi Xinan Wang Yvonne Li

Supplementary Figure 22. Proportion of (A) tumor, (B) non-tumor, and (C) total PD-L1+ cells in ATMMUT and ATMWT NSCLCs.

10.1158/1078-0432.23626978.v1

Cite

Citations (0)

Supplementary Figure 17 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of ATM Mutations in Non–Small Cell Lung Cancer

Biagio Ricciuti Arielle Elkrief Joao V. Alessi Xinan Wang Yvonne Li

Supplementary Figure 17. (A) Objective response rate, (B) progression-free survival, and (C) overall survival to PD-(L)1 inhibition among patients with advanced/metastatic NSCLC, according to ATM expression by immunohistochemistry.

10.1158/1078-0432.23627002.v1

Cite

Citations (0)

Supplementary Figure 2 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of ATM Mutations in Non–Small Cell Lung Cancer

Biagio Ricciuti Arielle Elkrief Joao V. Alessi Xinan Wang Yvonne Li

Supplementary Figure 2. Proportion of samples with PD-L1 TPS ≥1%, ≥50%, ≥90% according to ATM mutation status (ATMMUT versus ATMWT).

10.1158/1078-0432.23626990.v1

Cite

Citations (0)

Supplementary Figure 3 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of ATM Mutations in Non–Small Cell Lung Cancer

Biagio Ricciuti Arielle Elkrief Joao V. Alessi Xinan Wang Yvonne Li

Supplementary Figure 3. Co-mutation plot showing co-occurrent and mutual exclusive mutations among (A) ATMMUT and (B) ATMWT NSCLCs.

Plot (graphics)

10.1158/1078-0432.23626948

Cite

Citations (0)

Supplementary Figure 27 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of ATM Mutations in Non–Small Cell Lung Cancer

Biagio Ricciuti Arielle Elkrief Joao V. Alessi Xinan Wang Yvonne Li

Supplementary Figure 27. Tumor mutational burden in NSCLC samples which underwent NGS at the DFCI and MSK according to ATM/TP53 co-mutation status.

10.1158/1078-0432.22893776

Cite

Citations (0)

Supplementary Figure 18 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of ATM Mutations in Non–Small Cell Lung Cancer

Biagio Ricciuti Arielle Elkrief Joao V. Alessi Xinan Wang Yvonne Li

Supplementary Figure 18. (A) Objective response rate, (B) progression-free survival, and (C) overall survival to PD-(L)1 immune checkpoint blockade monotherapy among patients with ATMMUT NSCLC, according to STK11 mutation. (D) Objective response rate, (E) progression-free survival, and (F) overall survival to PD-(L)1 immune checkpoint blockade in combination with platinum doublet chemotherapy among patients with ATMMUT NSCLC, according to STK11 mutation.

STK11

Immune checkpoint

10.1158/1078-0432.22893809.v1

Cite

Citations (0)